Report Detail
U.S. Markets for General and Pelvic Endoscopic Surgery Products, May 2014
The rapid expansion of general laparoscopic surgery in the U.S. has been driven by patient demand for less invasive procedures as well as by the introduction of innovative endoscopic devices that have allowed many surgeons to become proficient in laparoscopic techniques. The laparoscope has been the most significant device affecting these changes, enabling procedures that are less invasive, low in cost, and require less time compared with open surgery. Surgical advances enabling small-incision, single-incision and incisionless procedures have necessitated the development of next-generation access systems, endoscopes/laparoscopes, hand instruments, robotic surgical systems, and other surgical devices and instruments. Overall, the transition among many surgical procedures from an open approach to minimally invasive methods has promoted a wider adoption of endoscopy/laparoscopy by many surgeons, which has benefited patients, as it reduces pain, recovery time, and scarring as well as hospital costs.
This dynamic, new report from Medtech Insight includes analyses of products, current/forecast markets, surgical procedure volumes, competitors, and opportunities in the U.S. General and Pelvic Endoscopic Surgery Products Market (focusing on general, pelvic/gynecologic, and urologic endoscopic procedures and related products). The 6 core product areas covered by the scope of this report include: endoscopic access devices, access site closure devices, insufflation products, endoscopes, hand instruments, and ancillary products (mechanical assist devices, smoke evacuation systems, and specimen retrieval bags).
During the forecast period covered by this report, the combined U.S. market for general and pelvic endoscopic surgery products is projected to increase from approximately $4.7 billion in 2013 to $6.5 billion in the year 2018. Growth in individual endoscopic device segments is expected to range from approximately 4.9% (for access devices), 8% (access site closure products), 4.9% (endoscopes), 7.8% (hand instruments), 6.5% (insufflation systems), and 6.3% (ancillary products) over the forecast period.